AIM Breakfasts

AIM BREAKFAST – 1st February 2017

Set Menu AIM:

Total number of AIM Companies (Incl Susp): 971

Total number of AIM Companies trading: 947*
* As at 31 January 2017

Dish of the Day:

No AIM Joiners Today

Off the Menu:

No AIM Leavers Today

Set Menu ISDX Growth:

Total number of ISDX Growth Market Companies (Incl Susp): 85*

Total number of ISDX Growth Market Companies trading: 81*
* As at 31 January 2017

Dish of the Day:

No NEX Growth Market Joiners Today

Off the Menu:

No NEX Growth Market Leavers Today

What’s Cooking in the IPO Kitchen?

Nando’s—According to a Reuters news release Nando’s has now denied speculation it was considering a London stock market flotation.

LXI REIT— Intention to float on the main market from the Company intending to invest in UK commercial property assets. Seeking an initial raise of £200m with authority for £200m more in first year,

Diversified Gas & Oil plc— AIM Admission now expected 3rd Feb. Raising $50m with expected market cap of $86.4m.

 

Breakfast Buffet

Metminco (MNC.L) 4.87p £4.4m

Metminco announced the completion of the second tranche of the placement of approximately A$4.85 million announced 17 November 2016, which will be used towards completing the Miraflores Bankable Feasibility Study (BFS) and to progress the project towards production.  Price of A$0.1185. The BFS is expected to complete in the current half year. The Company is targeting an annual gold production of 50,000 oz and secured up to US$45 million in funding for the Los Calatos Copper Project in Peru in which the Company currently holds a 49% interest.

 

China Africa Resources (CAF.L) 2.88p £2.18m

The natural resource exploration and development company has agreed to acquire a 48.88% stake in private Australian company Global Exploration Technologies, which  has five exploration licences in the Kalahari Copper Belt in Botswana held through three Botswanan subsidiary companies. This transaction does not constitute a reverse takeover under the AIM Rules and consequently China Africa must continue to seek to complete a reverse takeover or face suspension from trading on AIM.

 

Epwin (EPWN.L) 100.75p £144.36m

FYDec16 trading update from the vertically integrated manufacturer of low maintenance building products, supplying the Repair, Maintenance and Improvement, new build and social housing sectors. Profits will be in line with expectations, with continued strong cash generation in challenging market conditions.  The performance of recent acquisitions continues to be encouraging. “2016 was another year of progress for Epwin.  We grew profits and had strong cash generation in challenging market conditions.  This reflects our strategy to broaden our product portfolio organically and through acquisition, enhance cross-selling and improve our operations.” FyDec16 rev £298m, PBT £24.4m, div 6.6p.

 

Cohort (CHRT.L) 440p £183.94m

The independent technology group, announced that it has acquired the minority (49.999%) holding in its subsidiary MCL for a cash consideration of £5.1m in line with the arrangements stated at the time of its acquisition in July 2014. This takes Cohort’s holding in MCL to 100%, and the total consideration, including deferred consideration paid to date, to £12.1m. The consideration has been paid out of Cohort’s existing financial resources. A further payment of approximately £2.0 million is expected to be made on or before 31 July 2017 reflecting a further earn out linked to MCL’s current order book and the minority holding’s share of the surplus cash in MCL.  The impact of this acquisition is expected to be earnings enhancing in the remainder of the financial year ending 30 April 2017. FYApr17E EPS 25.7p.

 

Byotrol (BYOT.L) 4.13p £11.06m

The specialist anti-microbial technology company, announced that John Langlands has been appointed as Chairman with effect from today’s date and that Nicholas Martel has stepped down as Chairman and as a Director, also with effect today.  Nicholas will remain with the Company for a further three months to ensure an orderly hand-over. John Langlands has considerable business, commercial and City experience having worked for a number of listed companies. He has been CEO since 2003 of British Polythene Industries Plc, a leading European producer of polythene films for packaging and agriculture. BPI was sold to RPC GROUP Plc in August 2016 and John left BPI at the end of January 2017 following the successful integration of BPI into RPC.  Issued 2.7m options exercisable at 4.125p.

 

Adgorithms (ADGO.L) 22p £13.58m

FYDec16 trading statement from the creators of an artificial intelligence marketing platform. The Company continues to execute its stated growth strategy and expects trading to be in line with management’s expectations. Adgorithms’ un-audited revenue for the period is expected to be approximately $16 million with an un-audited adjusted EBITDA loss of approximately $8 million. The cash balance as of 31 December 2016 is expected to be approximately $22 million reflecting the Company’s focus on controlling cash burn.

 

Coal of Africa (CZA.L) 3.51p £67.64m

The coal exploration and project development company operating in South Africa, and traded on the ASX, AIM and the JSE, announced the successful completion of a share placement to M&G Investment Management Limited raising $2m at 4.081 cents. The proceeds will be used for working capital purposes. “The M&G placement once again confirms the support from our large shareholders and provides the Company with additional financial capacity to fund our working capital requirements. We remain committed to creating shareholder wealth by continuing to complete our turnaround strategy, a potential acquisition of a cash generator and ultimately the development of our flagship project – the Makhado Mine.”

 

AFH Financial (AFHP.L) 165p £39.81m

The financial planning led wealth management firm, has acquired the assets of Taylor Frost Wealth Management Limited, an IFA business based in South West London. Following the acquisition Keith Taylor will join AFH as an adviser. The maximum consideration payable by AFH is £1,245,000.  An initial cash consideration of £595,000 has been paid upon completion, satisfied from the Company’s existing cash resources. Further deferred consideration of up to £650,000 will be payable in cash over the next 26 months in two tranches, dependent upon performance criteria of the assets acquired.  Fourth acquisition of the current financial year. This deal adds circa £45m in funds under management.

 

Circle Holdings (CIRC.L) 21.63p £51.09m

The largest partnership of doctors, nurses and healthcare professionals in the UK has disposed of its land in Manchester to the Department for Communities and Local Government for cash consideration of £9.1 million plus VAT. The net proceeds from the disposal will be used for working capital purposes and to fund future growth opportunities, including the proposed new build hospital in Birmingham. The book value of the Manchester land as at 30 June 2016 was £5 million.

 

Quantum Pharma (QP.L) 48p £81.18m

FY Jan17 trading update from the service-led niche pharmaceutical developer, manufacturer and supplier.  Adjusted EBITDA for the year ended is expected to be in line with market expectations. The level of net debt is expected to be in the region of £13.5 million as cash management continues to be a key focus for the Group. Raised £15m in November 2016. As a result of actions to tighten strategic focus, the current performance of the Group is supportive of market expectations for the year ending 31 January 2018. FYJan18E rev of £85.12 and PBT of £7.46m.

 

Head Chef:

Derren Nathan
0203 764 2344
derren.nathan@hybridan.com

*A corporate client of Hybridan LLP

Disclaimer

This document, which does not constitute research, has been issued by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific entity and is not a personal recommendation to anyone. Recipients should make their own investment decisions based upon their own financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.

The information contained in this document is based on materials and sources that are believed to be reliable; however, they have not been independently verified and are not guaranteed as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, directors, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information in this document nor should it be relied upon as such.

Any and all opinions expressed are current opinions as of the date appearing on this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, directors, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.

This document should not be relied upon as being an independent or impartial view of the subject matter and, for the avoidance of doubt, does not constitute “independent investment research” for the purposes of the Financial Conduct Authority rules. The individuals who prepared this document may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, directors, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.

In the UK, this document is directed at and is for distribution only to persons who (i) fall within Article 19(5) (persons who have professional experience in matters relating to investments) or Article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended) or (ii) are Professional Clients or Eligible Counterparties (as those terms are defined in the rules of the Financial Conduct Authority) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as “relevant persons”). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by persons who would be classified as Retail Clients (as defined by the rules of the Financial Conduct Authority).

Neither this document nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of UK or US securities law, or the law of any such other jurisdictions.

Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, directors, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.

Neither the whole nor any part of this document may be duplicated in any form or by any means. Neither should this document, or any part thereof, be redistributed or disclosed to anyone without the prior consent of Hybridan LLP.
Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX. If you would like to unsubscribe, please email enquiries@hybridan.com with “unsubscribe me”.